Filter

371 - 380 of 559 Results

  • Mental Health Financing in the United States: A Primer

    Report

    This primer provides an overview of behavioral health care, reviews the sources of financing for such care, assesses the interaction between different payers, and highlights recent policy debates in mental health.

  • Medicare Part D 2010 Data Spotlight: Coverage of Top Brand-Name and Specialty Drugs

    Issue Brief

    This Part D Data Spotlight documents the wide variations across the private stand-alone drug plans with respect to coverage of drugs, what enrollees pay for those drugs, and restrictions and limitations placed on their use. These variations have potentially significant implications for beneficiaries’ access to medications and out-of-pocket costs.

  • The Nuts and Bolts of Medicare Premium Support Proposals

    Issue Brief

    In April 2011, as part of its 2012 budget resolution, the U.S. House included a proposal to reduce Medicare spending by transforming the program into a system sometimes called "premium support" or vouchers.

  • NGO Engagement in U.S. Global Health Efforts: U.S.-Based NGOs Receiving USG Support Through USAID

    Report

    This report provides an analysis of U.S.-based non-governmental organizations (NGOs) that received global health funding from the U.S. government (USG) during FY 2013. It specifically focuses on funding provided to NGOs by the U.S. Agency for International Development (USAID), the largest implementer of global health activities among USG agencies and departments.

  • Global Financing for Malaria: Trends & Future Status

    Report

    This report finds that funding for global malaria control and elimination activities has risen from US$871 million in 2005 to US$2.6 billion in 2013. However, total funding is significantly below US$5.1 billion, the goal set by the Global Malaria Action Plan, which is a framework endorsed by world leaders in 2008 to reach global malaria reduction targets.
    Additionally, support for malaria research and development (R&D) activities in 2013 was estimated to be US$549 million, below the estimated annual need of US$750-900 million and the lowest level of funding since 2007, the first year of available data.